Home Newsfeeds Rosenblatt Reiterates Neutral on Luminar Technologies, Maintains $8 Price Target

Rosenblatt Reiterates Neutral on Luminar Technologies, Maintains $8 Price Target

Rosenblatt analyst Kevin Cassidy reiterates Luminar Technologies (NASDAQ:LAZR) with a Neutral and maintains $8 price target.

byBenzinga Newsdesk

March 1, 2023

1 minute read

Rosenblatt analyst Kevin Cassidy reiterates Luminar Technologies (NASDAQ:LAZR) with a Neutral and maintains $8 price target.

Dawkoins Skyrockets 400% In A Single Day Following Richard Dawkins’ Birthday Celebration — Dogecoin, Shiba Inu Left In The Dust

By Mehab Qureshi

March 27, 12:19 AM

A new meme token named Dawkoins (DWK) has seen a rise of 400% in value in just 24 hours, outperforming well-known meme-based cryptocurrencies such as Dogecoin (CRYPTO: DOGE) and Shiba Inu (CRYPTO: SHIB).

$DOGE

Toast Stock Jumps In After Hours: What’s Driving The Action?

By Adam Eckert

November 10, 6:35 PM

Toast Inc (NYSE: TOST) shares are trading higher in Thursday's after-hours session after the company reported better-than-expected financial results and

TOST

On Jan 14, Intercept Pharmaceuticals And Unit Entered Into A Settlement Agreement With Optimus Pharma Pvt. And Optimus Drugs Pvt.; Granted Optimus Non-exclusive, Royalty-Free License To Commercialize Generic Version Of Ocaliva In U.S. From April 26, 20…

By Benzinga Newsdesk

January 17, 9:09 AM

- Form 8 Filing

ICPT

Tiptree Q3 EPS $0.38 Up From $0.06 YoY, Sales $363.50M Up From $286.61M YoY

By Benzinga Newsdesk

November 2, 5:43 PM

Tiptree (NASDAQ:TIPT) reported quarterly earnings of $0.38 per share. This is a 533.33 percent increase over earnings of $0.06 per share from the same period last year. The company reported $363.50 million in sales this

TIPT

Rosenblatt Reiterates Neutral on Luminar Technologies, Maintains $8 Price Target

Related Posts

Dawkoins Skyrockets 400% In A Single Day Following Richard Dawkins’ Birthday Celebration — Dogecoin, Shiba Inu Left In The Dust

Toast Stock Jumps In After Hours: What’s Driving The Action?

On Jan 14, Intercept Pharmaceuticals And Unit Entered Into A Settlement Agreement With Optimus Pharma Pvt. And Optimus Drugs Pvt.; Granted Optimus Non-exclusive, Royalty-Free License To Commercialize Generic Version Of Ocaliva In U.S. From April 26, 20…

Tiptree Q3 EPS $0.38 Up From $0.06 YoY, Sales $363.50M Up From $286.61M YoY